Eckhardt Gail Sue's Insider Trades & SAST Disclosures
Eckhardt Gail Sue's most recent trade in Exelixis Inc was a trade of 7,712 Common Stock done at an average price of $35.0 . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Eckhardt Gail Sue.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | Sue Gail Eckhardt | Director | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 14 Feb 2025 | 7,712 | 34,262 (0%) | 0% | 35.0 | 269,997 | Common Stock |
| Exelixis Inc | Sue Gail Eckhardt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.24 per share. | 14 Feb 2025 | 7,712 | 41,974 (0%) | 0% | 23.2 | 179,227 | Common Stock |
| Exelixis Inc | Sue Gail Eckhardt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 7,712 | 23,136 | - | - | Option (right to buy) | |
| Exelixis Inc | Sue Gail Eckhardt | Director | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 14 Feb 2025 | 3,856 | 30,406 (0%) | 0% | 35.0 | 135,114 | Common Stock |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 16,000 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 34,262 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Eckhardt Gail Sue | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 30,848 | 30,848 | - | - | Option (right to buy) | |
| Exelixis Inc | Eckhardt Sue Gail | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 15,424 | 15,424 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 12,000 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Sue Gail Eckhardt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2020 | 35,000 | 35,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges